Today in Mexico City we launched the combination of encorafenib and binimetinib approved for adult patients with inoperable or metastatic melanoma positive at BRAF V600 mutation – Paolo A. Ascierto
Today in Mexico City we launched the combination of encorafenib and binimetinib approved for the treatment of adult patients with inoperable or metastatic melanoma positive at BRAF V600 mutation. Encorafenib is an inhibitor that blocks the activity of some mutated forms of the BRAF kinases. Binimetinib is an inhibitor that blocks the activity of MEK1 and MEK2 kinases. COLUMBUS study already highlighted some years ago that encorafenib + binimetinib and enco alone improved 5-year PFS and OS vs vemurafenib in patients with BRAF V600E/K–mutant metastatic melanoma. In the last studies, we retrospectively investigated genetic and transcriptional correlates of response and intrinsic resistance to encorafenib + binimetinib in an exploratory biomarker analysis of COLUMBUS Part 1 and found out that patients with high immune-related signatures derived greater clinical benefit from enco + bini vs vemurafenib. High ErbB2 exp and PI3KCA pathway mutations are potential resistance mechanisms to enco + bini. Addition of checkpoint inhibitors or PI3KCA pathway–targeted therapies to enco + bini in selected patients may further improve clinical benefit for patients with BRAF V600E/K–mutant metastatic melanoma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023